For patients with a large and histologically aggressive PEComa, we think that neoadjuvant treatment with mTOR-inhibitor sirolimus may be considered to facilitate surgery and allow early control of a potentially metastatic disease. Here, MTOR is linked to neoplasm with perivascular epithelioid cell differentiation.